Literature DB >> 24598857

A decisional algorithm to start iron chelation in patients with beta thalassemia.

Fabrice Danjou1, Zvi Ioav Cabantchik, Raffaella Origa, Paolo Moi, Michela Marcias, Susanna Barella, Elisabetta Defraia, Carlo Dessì, Maria Loreta Foschini, Nicolina Giagu, Giovan Battista Leoni, Maddalena Morittu, Renzo Galanello.   

Abstract

Entities:  

Keywords:  RBC; iron chelation; percentage transferrin saturation; start; thalassemia major

Mesh：

Substances：

Year:  2014        PMID： 24598857      PMCID： PMC3943330          DOI： 10.3324/haematol.2013.098202

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload.

Authors:  L J Anderson; S Holden; B Davis; E Prescott; C C Charrier; N H Bunce; D N Firmin; B Wonke; J Porter; J M Walker; D J Pennell
Journal:  Eur Heart J       Date:  2001-12       Impact factor: 29.983

Review 2.  Intracellular and extracellular labile iron pools.

Authors:  Z Ioav Cabantchik; Or Kakhlon; Silvina Epsztejn; Giulianna Zanninelli; William Breuer
Journal:  Adv Exp Med Biol       Date:  2002       Impact factor: 2.622

3.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Authors:  J B Porter; R D Abeysinghe; L Marshall; R C Hider; S Singh
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

4.  Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

Authors:  M A Tanner; R Galanello; C Dessi; M A Westwood; G C Smith; S V Nair; L J Anderson; J M Walker; D J Pennell
Journal:  J Cardiovasc Magn Reson       Date:  2006       Impact factor: 5.364

5.  Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients.

Authors:  Athanasios Christoforidis; Afroditi Haritandi; Ioannis Tsitouridis; Ioanna Tsatra; Haido Tsantali; Stavroula Karyda; Athanasios S Dimitriadis; Miranda Athanassiou-Metaxa
Journal:  J Pediatr Hematol Oncol       Date:  2006-05       Impact factor: 1.289

6.  Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.

Authors:  William Breuer; Hussam Ghoti; Ahmmad Shattat; Ada Goldfarb; Ariel Koren; Carina Levin; Eliezer Rachmilewitz; Z Ioav Cabantchik
Journal:  Am J Hematol       Date:  2011-11-28       Impact factor: 10.047

7.  Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.

Authors:  Giuliana Zanninelli; William Breuer; Zvi I Cabantchik
Journal:  Br J Haematol       Date:  2009-09-18       Impact factor: 6.998

8.  Liver iron concentrations and urinary hepcidin in beta-thalassemia.

Authors:  Raffaella Origa; Renzo Galanello; Tomas Ganz; Nicolina Giagu; Liliana Maccioni; Gavino Faa; Elizabeta Nemeth
Journal:  Haematologica       Date:  2007-05       Impact factor: 9.941

9.  Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.

Authors:  Pensri Pootrakul; William Breuer; Matias Sametband; Pornpan Sirankapracha; Chaim Hershko; Z Ioav Cabantchik
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

10.  High nontransferrin bound iron levels and heart disease in thalassemia major.

Authors:  Antonio Piga; Filomena Longo; Lorena Duca; Simona Roggero; Tiziana Vinciguerra; Roberto Calabrese; Chaim Hershko; Maria Domenica Cappellini
Journal:  Am J Hematol       Date:  2009-01       Impact factor: 10.047
View more
  6 in total

1.  Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

Authors:  Louise de Swart; Jan C M Hendriks; Lisa N van der Vorm; Z Ioav Cabantchik; Patricia J Evans; Eldad A Hod; Gary M Brittenham; Yael Furman; Boguslaw Wojczyk; Mirian C H Janssen; John B Porter; Vera E J M Mattijssen; Bart J Biemond; Marius A MacKenzie; Raffaella Origa; Renzo Galanello; Robert C Hider; Dorine W Swinkels
Journal:  Haematologica       Date:  2015-09-18       Impact factor: 9.941

Review 2.  The Labile Side of Iron Supplementation in CKD.

Authors:  Itzchak Slotki; Zvi Ioav Cabantchik
Journal:  J Am Soc Nephrol       Date:  2015-05-21       Impact factor: 10.121

Review 3.  Estimating tissue iron burden: current status and future prospects.

Authors:  John C Wood
Journal:  Br J Haematol       Date:  2015-03-12       Impact factor: 6.998

4.  Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies.

Authors:  Eva Rombout-Sestrienkova; Lloyd Brandts; Ger H Koek; Cees Th B M van Deursen
Journal:  J Clin Apher       Date:  2021-12-13       Impact factor: 2.605

5.  Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia.

Authors:  Susi Susanah; Ponpon S Idjradinata; Nur M Sari; Lulu E Rakhmilla; Yunia Sribudiani; Jessica O Trisaputra; Octawyana Moestopo
Journal:  Biomed Res Int       Date:  2020-12-13       Impact factor: 3.411

Review 6.  Labile iron in cells and body fluids: physiology, pathology, and pharmacology.

Authors:  Zvi Ioav Cabantchik
Journal:  Front Pharmacol       Date:  2014-03-13       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.